Endra Life Sciences INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
ENDRA Life Sciences reports a net loss of $1.3 million for Q1 2026 while facing Nasdaq delisting risks due to equity deficiencies.
NASDAQ
ENDRA Life Sciences reported reduced net losses and operating expenses for Q3 2025, while initiating a Digital Asset Treasury strategy and addressing Nasdaq listing compliance.
NASDAQ
ENDRA Life Sciences reported a significantly reduced net loss in the first half of 2025, while announcing a new, unproven cryptocurrency treasury strategy and ongoing capital needs.
NASDAQ
ENDRA Life Sciences reports a reduced net loss for Q1 2025 compared to Q1 2024, as the company focuses on commercializing its TAEUS technology while addressing ongoing financial challenges.
NASDAQ
10-Q/A: ENDRA Life Sciences Amends Quarterly Report to Include Inline XBRL Tagging, Provides Business Update
ENDRA Life Sciences has amended its quarterly report for the period ended September 30, 2024, solely to add inline XBRL tagging, while also providing an update on its financial condition and business operations.
NASDAQ
ENDRA Life Sciences reported a net loss of $2.35 million for the third quarter of 2024 and is continuing to develop its TAEUS technology while facing financial challenges.
NASDAQ
10-Q: ENDRA Life Sciences Reports Q2 2024 Results, Outlines Path to FDA Approval and Leadership Changes
ENDRA Life Sciences reported its second quarter 2024 results, highlighting ongoing efforts to secure FDA approval for its TAEUS system and announcing key leadership changes.
NASDAQ
ENDRA Life Sciences reported a net loss of $2.78 million for the first quarter of 2024 and is facing challenges related to its ability to continue as a going concern.